NasdaqGM:KYMRBiotechs
Assessing Kymera Therapeutics (KYMR) Valuation After Fast Track Win For KT-621 And Gilead Deal For KT-200
Kymera Therapeutics (KYMR) is back in focus after the FDA granted Fast Track status to its oral STAT6 degrader KT-621 for eosinophilic asthma, alongside Gilead securing global rights to Kymera’s CDK2 degrader KT-200.
See our latest analysis for Kymera Therapeutics.
The recent Fast Track news and the KT-200 deal with Gilead come after a strong run, with Kymera’s 30 day share price return of 8.64% and 1 year total shareholder return of 155.29% signaling strong momentum around the pipeline...